Anteris Technologies Global Corp. Common Stock (AVR) - Total Liabilities

Latest as of June 2026: $20.84 Million USD

Based on the latest financial reports, Anteris Technologies Global Corp. Common Stock (AVR) has total liabilities worth $20.84 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Anteris Technologies Global Corp. Common current assets vs equity to evaluate short-term liquidity relative to the company's equity base.

Anteris Technologies Global Corp. Common Stock - Total Liabilities Trend (2020–2025)

This chart illustrates how Anteris Technologies Global Corp. Common Stock's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Anteris Technologies Global Corp. Common asset portfolio.

Anteris Technologies Global Corp. Common Stock Competitors by Total Liabilities

The table below lists competitors of Anteris Technologies Global Corp. Common Stock ranked by their total liabilities.

Company Country Total Liabilities
Tangrenshen Group Co Ltd
SHE:002567
China CN¥11.42 Billion
Pakuwon Jati Tbk
JK:PWON
Indonesia Rp10.08 Trillion
Anhui Zhonghuan Environmental Protection Technology Co Ltd
SHE:300692
China CN¥3.39 Billion
Sheela Foam Limited
NSE:SFL
India Rs18.57 Billion
Beijing Global Safety Technology Co Ltd
SHE:300523
China CN¥2.78 Billion
Shenzhen Fuanna Bedding and Furnishing Co Ltd
SHE:002327
China CN¥833.13 Million
Haining China Leather Market Co Ltd
SHE:002344
China CN¥4.54 Billion
Lian Hwa Foods Corp
TW:1231
Taiwan NT$7.70 Billion

Liability Composition Analysis (2020–2025)

This chart breaks down Anteris Technologies Global Corp. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See AVR net asset quality score to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 14.20 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.08 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.08 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Anteris Technologies Global Corp. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Anteris Technologies Global Corp. Common Stock (2020–2025)

The table below shows the annual total liabilities of Anteris Technologies Global Corp. Common Stock from 2020 to 2025.

Year Total Liabilities Change
2025-12-31 $23.25 Million +29.04%
2024-12-31 $18.02 Million +54.93%
2023-12-31 $11.63 Million +67.27%
2022-12-31 $6.95 Million -36.27%
2021-12-31 $10.91 Million +38.12%
2020-12-31 $7.90 Million --

About Anteris Technologies Global Corp. Common Stock

NASDAQ:AVR USA Medical Devices
Market Cap
$749.46 Million
Market Cap Rank
#10281 Global
#2742 in USA
Share Price
$7.69
Change (1 day)
+0.52%
52-Week Range
$3.38 - $10.57
All Time High
$10.57
About

Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT ant… Read more